Providing stock analysis for investors of the Canadian junior markets
Cytophage Technologies (TSXV: CYTO) has officially launched trials with one of the largest poultry hatcheries in Canada. The trial will see Cytophage’s OvaPhage product used to target harmful bacteria on the surface of eggs.
Read more
Cytophage Technologies (TSXV: CYTO) announced a landmark agreement this morning that will see the establishment of Manitoba’s first Phage Clinical Treatment Program. The program will aim to offer new options for patients to manage antibiotic-resistant infections.
Read more
In this interview, Dr. Steven Theriault, CEO & Chief Science Officer of Cytophage Technologies (TSXV: CYTO), discusses the company’s innovative approach to addressing bacterial infections through bacteriophage technology.
Read more
Cytophage Technologies (TSXV: CYTO) has announced the launch of a new product that it believes will set itself apart within the phage industry globally.
Read more
In this interview, Dr. Steven Theriault, CEO of Cytophage Technologies Ltd. (TSXV:CYTO), presents phage therapy as a potentially revolutionary biotech solution. He illustrates its efficacy by citing a successful treatment of a severe infection in Ottawa, underscoring the increasing demand for alternative treatments to combat antibiotic resistance.
Read more
Cytophage Technologies (TSXV: CYTO) is focusing its efforts on expanding the commercialization of its phage products within the Asian poultry market.
Read more
Cytophage Technologies (TSXV: CYTO) has added bench strength to its board of directors this morning, adding a thirty year pharmaceutical and biotech executive to its board.
Read more
Cytophage Technologies (TSXV: CYTO) has filed its fiscal 2023 results, providing a recap on a successful year in terms of corporate development while providing an outline of where the company is headed in 2024.
Read more
A 79-year-old resident from the Ottawa area credits an experimental treatment developed in Winnipeg with saving her life from a chronic artificial joint infection.
Read more
Cytophage Technologies (TSXV: CYTO) has seen early success in a recently completed human trial conducted at The Ottawa Hospital. The trial, which saw the use of its phages for the treatment of an antibiotic-resistant prosthetic joint infection, was the first time in Canada that phages were used for the treatment of a joint replacement infection.
Read more